Alimentary TractTwo-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments
Introduction
Helicobacter pylori infection is the main known cause of gastritis, gastroduodenal ulcer disease, and gastric cancer [1]. However, despite more than 30 years of experience in H. pylori treatment, the ideal regimen to treat this infection remains undefined. Consensus conferences have recommended therapeutic regimens that achieve cure rates higher than 80% on an intention-to-treat basis [2]. However, large clinical trials and meta-analyses have shown that the most commonly used first-line therapies – a proton pump inhibitor (PPI) plus 2 antibiotics – can fail in ≥20% of patients, and, in clinical practice, this rate might be even higher [1], [3]. Moreover, during the last few years, the efficacy of standard triple regimens has been decreasing, and several studies have reported intention-to-treat eradication rates lower than 75% and even lower than 50% [4]. Antibiotic resistance to clarithromycin has been identified as one of the major factors affecting our ability to cure H. pylori infection, and the rate of resistance to this antibiotic seems to be increasing in many geographic areas [5].
A rescue regimen comprising a quadruple combination of a PPI, bismuth, tetracycline, and metronidazole has been used as the optimal second-line approach based on the relatively good results reported [6], [7]. However, administration of the regimen is complex and adverse events are relatively common [6], [7]. Furthermore, the quadruple regimen still fails to eradicate H. pylori in approximately 20–30% of cases. Finally, bismuth salts are no longer available worldwide. Therefore, management of first-line eradication failures is becoming challenging.
Non-bismuth quadruple “sequential” and “concomitant” regimens, including a PPI, amoxicillin, clarithromycin and a nitroimidazole, are increasingly used as first-line treatments for H. pylori infection [8], [9]. However, eradication with rescue regimens may be challenging after failure of key antibiotics such as clarithromycin and nitroimidazoles.
Recent findings indicate that fluoroquinolones such as levofloxacin could prove to be an efficacious alternative to standard antibiotics, not only as first-line therapies but also, and more interestingly, as second-line regimens [10], [11], [12]. We previously obtained “intermediate” results (74% eradication rate) with a combination of a PPI, amoxicillin, and levofloxacin given for 10 days in multicenter studies performed in Spain [13], [14]. On the other hand, recent studies suggest that the efficacy of levofloxacin-containing therapy is decreasing, most likely due to increased primary quinolone resistance [15].
Moxifloxacin is a second-generation fluoroquinolone with a wide antibacterial spectrum [16]. Studies in vitro have shown that moxifloxacin has an improved coverage of Gram-positive and anaerobic bacteria while retaining good activity against Gram-negative bacteria [16]. Moxifloxacin has a higher in vitro activity against gram-positive and anaerobic pathogens compared with levofloxacin [17]. In vitro studies have shown excellent susceptibility of H. pylori strains to moxifloxacin [18], and clinical trials have confirmed its higher effectiveness – as a first-line therapy – compared with standard clarithromycin-based triple therapy [19]. Furthermore, few studies have suggested that the emergence of bacterial resistance appears to be less common for moxifloxacin than for other fluoroquinolones, and that moxifloxacin may be less affected by quinolone resistance than levofloxacin in H. pylori [18] and other bacterial infections [20], [21].
Therefore, the aim of the present study was to evaluate the efficacy and tolerability of a second-line triple regimen containing moxifloxacin in patients whose previous H. pylori eradication treatment failed.
Section snippets
Patients
This was a prospective multicenter study (21 Hospitals, 19 Spanish and 2 Italian) including consecutive patients in whose first-line therapy [standard triple therapy (PPI, clarithromycin, and amoxicillin) or a non-bismuth quadruple therapy (PPI, clarithromycin, amoxicillin and metronidazole), either sequentially or concomitantly] had failed to eradicate H. pylori infection. Previous failure was defined as a positive 13C-urea breath test result 4–8 weeks after completion of treatment. The
Demographic variables
The study sample comprised 250 patients (21 centres, inclusion per centre ranged from 2 to 48, median inclusion was 6), of whom 89% had functional or non-investigated dyspepsia, and 11% peptic ulcer disease. Mean age was 48 ± 15 years, 58% were women, and 15% were smokers.
Previous treatments
Previous (failed) therapy included: standard triple therapy (PPI–clarithromycin–amoxicillin; 179 patients, 71%), sequential therapy (PPI–amoxicillin for 5 days, plus PPI–clarithromycin–metronidazole for another 5 days; 27
Discussion
In this large multicenter study we have shown that 14-day moxifloxacin-containing therapy is an effective second-line strategy in patients whose previous H. pylori therapy has failed, achieving an eradication rate >80% both by per-protocol and by intention-to-treat.
Moxifloxacin is a second-generation fluoroquinolone with a broad spectrum of activity compared with the first generation [16]. Initially, the combination of a PPI, amoxicillin, and moxifloxacin as the first-line regimen was
Conflict of interest
None declared.
References (58)
- et al.
Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007–2012)
Gastroenterologia y Hepatologia
(2013) - et al.
Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication
Digestive and Liver Disease
(2009) - et al.
Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment
Digestive and Liver Disease
(2010) - et al.
Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance
Digestive and Liver Disease
(2007) - et al.
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice
Digestive and Liver Disease
(2010) - et al.
Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility
International Journal of Antimicrobial Agents
(2007) Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection?
Gastroenterologia y Hepatologia
(2008)- et al.
Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies
Clinical Therapeutics
(2004) - et al.
Helicobacter pylori infection
New England Journal of Medicine
(2010) - et al.
Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report
Gut
(2012)
The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough
Alimentary Pharmacology and Therapeutics
Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption
Gut
Review article: Helicobacter pylori rescue regimen when proton pump inhibitor-based triple therapies fail
Alimentary Pharmacology and Therapeutics
“Rescue” regimens after Helicobacter pylori treatment failure
World Journal of Gastroenterology
Sequential therapy for Helicobacter pylori eradication: a critical review
Journal of Clinical Gastroenterology
Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
Clinical and Experimental Gastroenterology
Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure
Alimentary Pharmacology and Therapeutics
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis
American Journal of Gastroenterology
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis
Wiener Klinische Wochenschrift
Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients
Journal of Clinical Gastroenterology
Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients
American Journal of Gastroenterology
Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics
Pharmacotherapy
Evaluation of the clinical microbiology profile of moxifloxacin
Clinical Infectious Diseases
Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients
Journal of Antimicrobial Chemotherapy
Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials
Internal Medicine
Resistance to fluoroquinolones and methicillin in ophthalmic isolates of Staphylococcus pseudintermedius from companion animals
Canadian Veterinary Journal
Antibiotic susceptibility patterns of bacteria isolated from keratitis and intraocular infections at Fundacion Oftalmologica de Santander (FOSCAL), Floridablanca, Colombia
Biomedica
The TETRA study: a prospective evaluation of Helicobacter pylori ‘test-and-treat’ strategy on 736 patients in clinical practice
Helicobacter
High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial
Wiener Klinische Wochenschrift
Cited by (17)
Helicobacter pylori treatment: New perspectives using current experience
2017, Journal of Global Antimicrobial ResistanceCitation Excerpt :pylori therapy using these antibacterial agents. Until now, most international guidelines recommended levofloxacin-based triple therapy as second- or third-line treatment against H. pylori infection [74,110,111]. Applications of fluoroquinolones in different therapeutic regimens are summarised in Tables 3–5 [103,104,112–129].
IV Spanish Consensus Conference on Helicobacter pylori infection treatment
2016, Gastroenterologia y HepatologiaThe Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
2016, GastroenterologyCitation Excerpt :The increasing prevalence of resistance and increasing rates of failure of current therapies emphasize the need to continue developing and evaluating new regimens. Moxifloxacin-containing triple therapies have been studied in some parts of the world.130–133 Several meta-analyses of RCTs have reported that this regimen is better tolerated than bismuth quadruple therapy and is as effective in the first-line setting130 and more effective in the second-line setting.130,131
Helicobacter pylori-associated diseases
2015, Gastroenterologia y HepatologiaWarnings on the safety of quinolones: Should Helicobacter pylori treatment prescriptions be modified?
2019, Gastroenterologia y HepatologiaEvidence based guidelines for the treatment of helicobacter pylori infection in Korea 2020
2021, Korean Journal of Internal Medicine